Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02426125 · ClinicalTrials.gov registry record · Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 530
- Enrollment target
NCT02426125: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02426125 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 530 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02426125, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 530 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
Primary Outcome
PFS defined as time from first day of therapy to first evidence of disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive Disease (PD) is at least 20% increase in sum of diameters of target lesions, with reference being the smallest sum on study and plus absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If participant does not have complete baseline disease assess
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG Ramucirumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2015-07-13 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 3 |
What the finished NCT02426125 record still lists
NCT02426125 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02426125 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02426125 about?
NCT02426125 is a clinical study titled "A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer". The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
What is the current status of trial NCT02426125?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 530 participants. The study started on 2015-07-13. Estimated completion is 2022-07-26.
What interventions are being tested in trial NCT02426125?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02426125?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02426125's enrollment target sits among peer trials
530 706th of 2000 higher than 1,292 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI